Patents by Inventor Heiner Glombik

Heiner Glombik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20230219937
    Abstract: The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn’s disease or ulcerative colitis.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 13, 2023
    Inventors: Elisabeth DEFOSSA, Heiner GLOMBIK, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Lothar SCHWINK, Hauke SZILLAT, Gernot ZECH
  • Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 10392366
    Abstract: The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: August 27, 2019
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Christoph Pöverlein, Kurt Ritter, Nis Halland, Matthias Lohmann
  • AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20180237419
    Abstract: The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 23, 2018
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Christoph Poverlein, Kurt Ritter, Nis Halland, Matthias Lohmann
  • Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9908868
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9896434
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9758520
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170029405
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 2, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022198
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022182
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 8853412
    Abstract: The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 7, 2014
    Assignee: Sanofi
    Inventors: Lothar Schwink, Martin Bossart, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Thomas Klabunde, Thomas Maier, Siegfried Stengelin
  • PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20140099333
    Abstract: The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 10, 2014
    Applicant: SANOFI
    Inventors: Lothar SCHWINK, Martin BOSSART, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Thomas KLABUNDE, Thomas MAIER, Siegfried STENGELIN
  • 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof
    Patent number: 8106023
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 31, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof
    Patent number: 8101583
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 24, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals
    Patent number: 8048901
    Abstract: The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: November 1, 2011
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Jochen Goerlitzer, Heiner Glombik, Eugen Falk, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Christian Stapper, Wolfgang Wendler
  • 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
    Patent number: 7956085
    Abstract: This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: June 7, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • 2-{-3,?2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes
    Patent number: 7956077
    Abstract: The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of formula I wherein the various substituent R-groups are more specifically defined herein.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: June 7, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Christian Stapper, Eugen Falk, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler, Stephanie Knieps
  • 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof
    Patent number: 7923468
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: April 12, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
    Publication number: 20110059910
    Abstract: The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.
    Type: Application
    Filed: August 6, 2010
    Publication date: March 10, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Wendelin FRICK, Heiner GLOMBIK, Stefan THEIS, Ralf ELVERT
  • Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
    Patent number: 7872034
    Abstract: The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: January 18, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Christian Stapper, Stefanie Keil, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
    Patent number: 7820804
    Abstract: The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 26, 2010
    Assignee: Sanofi-Aventia Deutschland GmbH
    Inventors: Harm Brummerhop, Wendeline Frick, Heiner Glombik, Oliver Plettenburg, Martin Bickel, Hubert Heuer, Stefan Theis